Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
85. Vogt E, Ng AK, Rote NS. Antiphos-phatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. Am J Obstet Gynecol 1997; 177: 964—972.
86. Rand JH, Wu XX, Andree HAM, Alexander Ross JB, Rosinova E, Gascon-Lema MG, Calandri C, Harpel PC. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant"phenomenon. Blood. 1998; 92: 1652—1660.
87. Carreras L, Forastiero R, Martinuzzo M: Interaction between antiphospholipid antibodies and eicosanoids. In Hughes Syndrome, Antiphospholipid Syndrome. Edited by Khamashta MA. London: Springer—Verlag; 2000: 337—347.
88. Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/ prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 2894—2899.
89. Алекберова ЗС, Решетняк ТМ, Насонов ЕЛ и др. Уровни тромбоксана и простацикли-на у больных системной красной волчанкой с антифосфолипидным синдромом. Клин. медицина, 1994; 6: 31—35.
90. Atsumi T, Khamashta MA, Haworth RS, Brooks G, Amengual O, Ichikawa K, Koike T, Hughes GR. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum 1998; 41: 800— 807.
91. Cho C-S, Cho M-L, Chen PP, et al. Antiphospholipid antibodies induce monocyte chemoattractant protein-1 in endothelial cells. J Immunol 2002; 168: 4209—4215.
92. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998; 41:1141—1151.
93. Кобылянский АГ, Кузнецова ТВ, Соболева ГН и др. Определение оксида азота в сыворотке и плазме крови человека. Метод высо-
SHS-OOO4.qxd 21.11.2006 16:56 Page 105
05
ГЛАВА 5. Патогенетические механизмы антифосфолипидного синдрома
коэффективной жидкостной хроматограф-фии. Биомедицинская химия, 2003; 6 с.
94. Shin Y-J, Min S-Y, Cho M-L, et al. Enhanced nitric oxide production in endothelial cells by antiphospholipid antibodies. ACR/ARHP Annual Acientific Meeting, 2003, October 24— 28; 320 (abst).
95. Emmi L, Bergamini C, Spinelli A, Liotta F, Marchione T, Caldini A, Fanelli A, De-Cristo-faro MT, Dal-Pozzo G. Possible pathogenetic role of activated platelets in the primary antiphospho-lipid syndrome involving the central nervous system. Ann N Y Acad Sci 1997; 823: 188—200.
96. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticar-diolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73: 529—534.
97. Nojima J, Suehisa E, Kuratsune H, Machii T, Koike T, Kitani T, Kanakura Y, Amino N. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythemato-sus-possible association with thrombotic and thrombocytopenic complications. Thromb Hae-most 1999; 81: 436—441.
98. Wiener MH, Burke M, Fried M, Yust I. Thromboagglutination by anticardiolipin antibody complex in the antiphospholipid syndrome. a possible mechanism of immune-mediated thrombosis. Thromb Res 2001; 103: 193—199.
99. Ferro D, Basili S, Roccaforte S, et al. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus, Arthritis Rheum 1999; 42: 2689—2697.
100. Reverter JC, Tassies D. Mechanisms of thrombosis in the antiphospholipid syndrome: binding to platelets. In Hughes Syndrome, Antiphospholipid Syndrome. Edited by Khamash-ta MA. London: Springer—Verlag; 2000: 290— 298.
101. Joseph JE, Harrison P, Mackie IJ, et al. Platelet activation markers and the primary antiphospholipid syndrome (PAPS). Lupus 1998; 7 (Suppl 2): S48— S51.
102. Reverter JC, Tassies D, Font J, et al.: Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor
expression on monocytes. Arthritis Rheum 1998; 41: 1420—1427.
103. Lackner KJ, von Landenberg C, Barlage S, et al. Analysis of prothrombotic effects of two human monoclonal IgG antiphospholipid antibodies of apparently similar specificity. Thromb Haemost 2000; 83: 583— 588.
104. Robbins DL, Leung S, Miller-Blair DJ, et al. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998; 25: 51—56.
105. George J, Gilburd B, Langevitz P, et al. Beta 2 glycoprotein I containing immune-complexes in lupus patients: association with throm-bocytopenia and lipoprotein (a) levels. Lupus 1999; 8: 116—120.
106. Vega-Ostertag M, Harris EN, Pierangeli SS, et al. Phosphorilation of P38MAPK is involved in antiphospholipid antibody mediated platelet activation. ACR/ARHP Annual Acientific Meeting, October, 2003; 24—28; 318 (abst).
107. Rock G, Chauhan K, Jamieson GA, et al. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol 1994; 88: 878—880.
